Long-Term Cost-Effectiveness of an Advanced Hybrid Closed-Loop Automated Insulin Delivery System Versus Multiple Daily Insulin Injections Plus Continuous Glucose Monitoring in Adults with Type 1 Diabetes in Australia.

Sarah Glastras^1,2, Meaghan Read³, Aslı Zeynep Ozdemir Saltik⁴, Marianne Huynh⁵, Gabrielle Challis⁵, Michelle Hill⁴, Martin Field⁶, Richard Pollock⁶, Simona de Portu⁴

¹Kolling Institute, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. sarah.glastras@sydney.edu.au.

²Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital, St Leonard's, Sydney, NSW, Australia. sarah.glastras@sydney.edu.au.

³Patient Author, Melbourne, VIC, Australia.

⁴Medtronic International Trading Sàrl, Tolochenaz, Switzerland.

⁵Medtronic, Macquarie Park, Sydney, NSW, Australia.

⁶Covalence Research Ltd, Harpenden, UK.

PubMed DOI

Abstract

INTRODUCTION: The MiniMed™ 780G (MM780G) advanced hybrid closed-loop system has been shown to help improve glycemic control compared with continuous glucose monitoring plus multiple daily injections of insulin (MDI) in people with type 1 diabetes (T1D). The long-term health economic outcomes with MM780G versus MDI + CGM in people with T1D in Australia and HbA1c levels above target were investigate…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.